Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
07 Novembro 2023 - 9:00AM
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage
biopharmaceutical company developing novel immunotherapies for the
treatment of cancer, today announced that management will
participate in a fireside chat at the Stifel 2023 Healthcare
Conference on Tuesday, Nov. 14, 2023, at 8:35 a.m. EDT (5:35 a.m.
PDT) in New York, New York.
A live webcast of the presentation will be
available on the Events and Presentations page of Bolt’s website at
www.boltbio.com. Archived replays will be available for 30 days
following the event.
About Bolt Biotherapeutics,
Inc.Bolt Biotherapeutics is a clinical-stage
biopharmaceutical company leveraging the immune system for a better
way to treat cancer. The company is developing novel
immunotherapies using an approach that teaches the immune system to
recognize and kill cancer in a way that is immediately personalized
to each patient. Its pipeline candidates are built on the Company’s
deep expertise in myeloid biology and cancer drug development and
include BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating
Antibody Conjugate (ISAC) being evaluated in a Phase 2 trial, and
BDC-3042, a myeloid-modulating agonist antibody targeting Dectin-2,
being evaluated in a Phase 1 trial. Bolt Biotherapeutics is also
developing multiple Boltbody™ ISACs in strategic collaborations
with leading biopharmaceutical companies. For more information,
please visit https://www.boltbio.com/.
Investor Relations and Media
Contact:
Maeve ConneightonArgot Partners(212)
600-1902boltbio@argotpartners.com
Bolt Biotherapeutics (NASDAQ:BOLT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Bolt Biotherapeutics (NASDAQ:BOLT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024